Alimera Sciences

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Alimera Sciences excels in Q1 2024, eyes revenue growth and market expansion

Alimera Sciences' Q1 2024 performance reflects robust revenue growth, profitability improvements, and strategic initiatives to drive product awareness and clinical advancements.
While facing challenges in margin stabilization and cost management, the company is well-positioned to capitalize on opportunities like indication expansion and sales optimization.
Overall, Alimera Sciences' strong financial performance, focus on innovation, and market expansion efforts position it for continued growth and success in the ophthalmic pharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alimera Sciences is a pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer. The company is passionate about protecting the retina and developing innovative treatments to preserve vision.

Conference Call to be held Wednesday July 27, at 9:00am Eastern Time Conference Call to be held Wednesday July 27, at 9:00am Eastern Time

Alimera Sciences to Report Second Quarter 2022 Financial Results on Wednesday, July 27, 2022, and Provide Corporate Update

Partner Horus Pharma to launch ILUVIEN for non-infectious uveitis affecting the posterior segment indication later in Q3 Partner Horus Pharma to launch ILUVIEN for non-infectious uveitis affecting the posterior segment indication later in Q3

Alimera Announces Pricing and Reimbursement of Uveitis Indication Granted for ILUVIEN® in France

ILUVIEN® data to be presented onsite at the annual American Society of Retina Specialists (ASRS) conference. ILUVIEN® data to be presented onsite at the annual American Society of Retina Specialists (ASRS) conference.

Alimera Announces Data to Be Highlighted In Scientific Programming At Annual Congress

ILUVIEN receives approval and pricing for non-infectious uveitis affecting the posterior segment indication in July; launch to follow ILUVIEN receives approval and pricing for non-infectious uveitis affecting the posterior segment indication in July; launch to follow

Alimera Announces Approval and Pricing Granted for ILUVIEN® for Uveitis in Italy

ATLANTA, June 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced today that its partner, Ocumension Therapeutics (“Ocumension”) received approval from the National Medical Products Administration for its IND application to begin the Phase III clinical study for fluocinolone acetonide intravitreal implant in support of a filing for marketing approval to treat diabetic macular edema in mainland China.

Phase III Clinical Study IND Accepted in China for Alimera's Fluocinolone Acetonide Intravitreal Implant

Recently presented data further demonstrate steroid challenge is highly predictive of IOP response post-FAc regardless of steroid choice Recently presented data further demonstrate steroid challenge is highly predictive of IOP response post-FAc regardless of steroid choice

Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to ILUVIEN® Use for IOP Outcomes

Alimera Sciences, Inc (NASDAQ:ALIM ) Q1 2022 Earnings Conference Call May 9, 2022 9:00 AM ET Company Participants Scott Gordon - CORE IR Richard Eiswirth - President and Chief Executive Officer Phil Jones - Chief Financial Officer Conference Call Participants Alexander Nowak - Craig-Hallum Capital Group James Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences First Quarter 2022 Financial Results and Corporate Update Conference Call.

Alimera Sciences, Inc (ALIM) CEO Richard Eiswirth on Q1 2022 Results - Earnings Call Transcript

ATLANTA, May 09, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the first quarter of 2022. Alimera will host a conference call on May 9th, 2022, at 9:00 a.m. ET to discuss these results and provide an update on corporate developments.

Alimera Sciences Reports First Quarter 2022 Results

Conference Call to be held the same day at 9:00am Eastern Time Conference Call to be held the same day at 9:00am Eastern Time

Alimera Sciences to Report First Quarter 2022 Financial Results on Monday, May 9, 2022, and Provide Corporate Update

Follow up ILUVIEN® PALADIN data to be presented onsite at the annual Association for Research in Vision and Ophthalmology (ARVO) conference Follow up ILUVIEN® PALADIN data to be presented onsite at the annual Association for Research in Vision and Ophthalmology (ARVO) conference

Recent Alimera Data Featured in Scientific Programming at Upcoming Annual Congress

ATLANTA, April 06, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced today that the company launched new corporate branding and has moved its global headquarters to a new, state-of-the-art facility.

Alimera Exhibits Continued Growth and Expansion With New Branding and Office Relocation

Alimera Sciences, Inc (ALIM) CEO Richard Eiswirth on Q4 2021 Results - Earnings Call Transcript

Alimera Sciences Reports Fourth Quarter and FY 2021 Results

ATLANTA, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced today that the 3-year results of the PALADIN study have been published in the peer-reviewed journal Ophthalmology.

Phase 4 PALADIN Study with ILUVIEN® Published in Peer-Reviewed Journal Ophthalmology

Conference Call to be held Thursday, February 24, 2022, at 9:00am Eastern Time Conference Call to be held Thursday, February 24, 2022, at 9:00am Eastern Time

Alimera Sciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022, and Provide Corporate Update

ATLANTA, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces that Rick Eiswirth, Alimera's President and Chief Executive Officer will present at the MicroCap Rodeo Winter Wonderland Best Ideas Virtual Investor Conference, which is being held virtually from February 8 – 11, 2022.

Alimera Sciences to Present at the MicroCap Rodeo Winter Wonderland Best Ideas Virtual Investor Conference

ATLANTA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that Rick Eiswirth, Alimera's President and Chief Executive Officer, will participate in two investor conference events in January.

Alimera Sciences to Participate in Upcoming January 2022 Investor Conferences

ATLANTA, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Erin Parsons to its Board of Directors. Ms. Parsons has more than 20 years of experience working in the ophthalmic industry overseeing scientific strategy, medical communications, advocacy development, and peer-to-peer educational programs, much of this in the retina space.

Alimera Sciences Welcomes Ophthalmic Strategic Consultant Erin Parsons to Its Board of Directors

ATLANTA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that Rick Eiswirth, Alimera's President and Chief Executive Officer, will participate in three investor conference events in November.

Alimera Sciences to Participate in Upcoming November 2021 Investor Conferences

Alimera Sciences, Inc. (ALIM) CEO Richard Eiswirth on Q3 2021 Results - Earnings Call Transcript

ATLANTA, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the third quarter of 2021. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.

Alimera Sciences Announces Third Quarter 2021 Financial Results

Conference Call to be held Thursday, October 28, 2021, at 9:00am Eastern Time Conference Call to be held Thursday, October 28, 2021, at 9:00am Eastern Time

Alimera Sciences to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021, and Provide Corporate Update

Alimera Sciences (ALIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Alimera Sciences (ALIM) to Report a Decline in Earnings: What to Look Out for

The stock price of Alimera Sciences Inc (NASDAQ: ALIM) increased by over 6% today. This is why it happened.

ALIM Stock: Why It Increased Today

PALADIN Study Data Presented at the American Society of Retina Specialists Shows That Post-ILUVIEN, the Percentage of Eyes Receiving One Yearly Treatment or Less Increased 3.2-Fold Compared to Pre-ILUVIEN

Recent 24-Month Real-World PALADIN Data Demonstrate the Ability of ILUVIEN® to Significantly Reduce Treatment Burden in Patients with Diabetic Macular Edema

News for Alimera Sciences Stock (ALIM)